근위축성측색경화증(ALS) 치료제 시장 예측(-2030년) : 약제 유형, 작용기서, 투여 경로, 병기, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Amyotrophic Lateral Sclerosis Therapeutics Market is accounted for $0.86 billion in 2024 and is expected to reach $2.31 billion by 2030 growing at a CAGR of 12.6% during the forecast period. Amyotrophic Lateral Sclerosis (ALS) therapeutics encompass a range of treatments aimed at managing symptoms, slowing disease progression, and improving quality of life for individuals with ALS, a neurodegenerative disorder affecting motor neurons in the brain and spinal cord. Therapeutics help alleviate symptoms such as muscle weakness, spasticity, and pain, improving patient comfort and quality of life.

According to the data published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,583 cases of amyotrophic lateral sclerosis were identified in the USA.

Market Dynamics:

Driver:

Increasing incidence rates

As more individuals are diagnosed with ALS, the demand for effective treatment options rises, driving research and development investments. Pharmaceutical companies are incentivized to innovate, leading to the introduction of novel therapies and clinical trials. Furthermore, heightened awareness and advocacy for ALS lead to increased funding and support for research initiatives. This growing patient population, coupled with advancements in understanding the disease, fuels market expansion by promoting the development of targeted and personalized treatment solutions.

Restraint:

Complex regulatory pathways

Complex regulatory pathways in Amyotrophic Lateral Sclerosis (ALS) therapeutics stem from the disease's rarity and its multifaceted nature. The need for extensive clinical trials, often involving diverse patient populations, can delay drug approvals. Stringent requirements for demonstrating efficacy and safety further complicate the process. Consequently, the slow progression of novel therapies reaching the market limits treatment options for patients and hampers overall market growth.

Opportunity:

Growing emphasis on multidisciplinary care and supportive therapies

ALS therapeutics approach integrates neurology, respiratory therapy, nutrition, and palliative care, enhancing patient quality of life and treatment outcomes. Collaborative care models promote the development of comprehensive treatment plans, driving demand for innovative therapeutics and supportive interventions. Additionally, heightened awareness of ALS and the need for personalized care encourage research investments and partnerships, leading to the emergence of novel therapies. This holistic approach fosters greater patient adherence and satisfaction, further propelling market growth.

Threat:

High treatment costs

High treatment costs in ALS therapeutics stem from the complexity of the disease, the need for advanced medications, and ongoing supportive therapies. Innovative treatments, often in limited supply, require significant research and development investment, resulting in elevated prices. These high costs can limit patient access, create financial burdens, and reduce adherence to treatment regimens. Consequently, this hampers market growth by restricting the patient population and reducing overall demand for ALS therapeutics, thus impacting the potential for new product development and market expansion.

Covid-19 Impact

The covid-19 pandemic significantly impacted the ALS therapeutics market by disrupting clinical trials and research activities, delaying the development and approval of new therapies. Patients faced challenges in accessing healthcare services, leading to interrupted treatment regimens and decreased patient monitoring. Additionally, the focus on COVID-19 diverted resources and funding away from ALS research. However, the pandemic also increased telehealth adoption, allowing for continued patient support and consultations, potentially benefiting long-term care strategies for ALS patients.

The riluzole segment is expected to be the largest during the forecast period

The riluzole segment is predicted to secure the largest market share throughout the forecast period. Riluzole is an FDA-approved drug used in the treatment of Amyotrophic Lateral Sclerosis (ALS). It is classified as a glutamate antagonist, working primarily by inhibiting the release of glutamate, a neurotransmitter that can contribute to neuronal damage when present in excess. Riluzole is shown to slow disease progression and extend survival in ALS patients, making it a critical therapeutic option.

The experimental therapies segment is expected to have the highest CAGR during the forecast period

The experimental therapies segment is anticipated to witness the highest CAGR during the forecast period. Experimental therapies for ALS offer promising benefits by targeting the disease's underlying mechanisms. By focusing on personalized medicine, these experimental treatments aim to enhance patient outcomes and quality of life. Moreover, they contribute to a deeper understanding of ALS, paving the way for future breakthroughs and expanding the therapeutic landscape for affected individuals.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness of the disease and rising incidence rates. Countries like Japan, China, and India are focusing on enhancing research and development efforts for effective therapies. Government initiatives aimed at improving healthcare infrastructure and patient access to treatments further support market expansion. Additionally, the growing emphasis on supportive care options enhances the overall management of ALS in this region.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period driven by advanced healthcare infrastructure and significant investment in research and development. The United States and Canada are leading in clinical trials for innovative therapies, with a focus on gene therapy and novel drug formulations. The presence of major pharmaceutical companies enhances competition and accelerates the development of effective ALS therapies. Additionally, comprehensive supportive care services improve patient outcomes and quality of life.

Key players in the market

Some of the key players profiled in the Amyotrophic Lateral Sclerosis Therapeutics Market include Teva Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., Eli Lilly and Company, Amgen Inc., Sanofi, Biogen Inc., Ionis Pharmaceuticals Inc., Orphazyme A/S, Regeneron Pharmaceuticals Inc., Reata Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Wave Life Sciences Limited, Cytokinetics Incorporated, NeuroSense Therapeutics Limited and Coya Therapeutics.

Key Developments:

In August 2024, NeuroSense Therapeutics Ltd. announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). This data provides additional insights that align with the Company's recent announcements of improved survival by 43% and slowed disease progression by 36%.

In June 2024, Coya Therapeutics recently announced the publication of a Phase 1 clinical trial that evaluated a novel combination therapy for Amyotrophic Lateral Sclerosis (ALS) in the peer-reviewed journal Frontiers in Neurology. The study explored the effects of a combination of CTLA4-Ig and low-dose interleukin-2 (IL-2) on ALS patients.

Drug Types Covered:

• Riluzole
• Edaravone
• Investigational Drugs
• Other Drug Types

Action Mechanisms Covered:

• Glutamate Inhibitors
• Free Radical Scavengers
• Neuroprotective Agents
• Combination Therapies
• Other Action Mechanisms

Route Of Administrations Covered:

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Disease Stages Covered:

• Early Stage
• Moderate Stage
• Advanced Stage

Applications Covered:

• Symptomatic Treatments
• Nutritional Support
• Respiratory Therapies
• Physical & Occupational Therapy
• Experimental Therapies
• Complementary Therapies
• Other Applications

End Users Covered:

• Hospitals
• Specialty Clinics
• Homecare Settings
• Research Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Drug Type

• 5.1 Introduction
• 5.2 Riluzole
• 5.3 Edaravone
• 5.4 Investigational Drugs
• 5.5 Other Drug Types

6 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Action Mechanism

• 6.1 Introduction
• 6.2 Glutamate Inhibitors
• 6.3 Free Radical Scavengers
• 6.4 Neuroprotective Agents
• 6.5 Combination Therapies
• 6.6 Other Action Mechanisms

7 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Route Of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Intravenous
• 7.4 Subcutaneous
• 7.5 Intramuscular

8 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Disease Stage

• 8.1 Introduction
• 8.2 Early Stage
• 8.3 Moderate Stage
• 8.4 Advanced Stage

9 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Application

• 9.1 Introduction
• 9.2 Symptomatic Treatments
• 9.3 Nutritional Support
• 9.4 Respiratory Therapies
• 9.5 Physical & Occupational Therapy
• 9.6 Experimental Therapies
• 9.7 Complementary Therapies
• 9.8 Other Applications

10 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Specialty Clinics
• 10.4 Homecare Settings
• 10.5 Research Institutions
• 10.6 Other End Users

11 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Teva Pharmaceutical Industries Limited
• 13.2 Novartis AG
• 13.3 Pfizer Inc.
• 13.4 Eli Lilly and Company
• 13.5 Amgen Inc.
• 13.6 Sanofi
• 13.7 Biogen Inc.
• 13.8 Ionis Pharmaceuticals Inc.
• 13.9 Orphazyme A/S
• 13.10 Regeneron Pharmaceuticals Inc.
• 13.11 Reata Pharmaceuticals Inc.
• 13.12 Apellis Pharmaceuticals Inc.
• 13.13 Wave Life Sciences Limited
• 13.14 Cytokinetics Incorporated
• 13.15 NeuroSense Therapeutics Limited
• 13.16 Coya Therapeutics